Use of Nesiritide in the Management of Acute Diastolic Heart Failure
Primary objective is to assess the effect of nesiritide in decreasing left ventricular (LV) filling pressure, defined as pulmonary artery capillary wedge pressure (PCWP) in a group of patients admitted with acute diastolic heart failure.
Secondary objectives include: improvement in symptoms, exercise tolerance, improvement in Doppler diastolic filling parameters in patients with diastolic heart failure.
Acute Heart Failure
Diastolic Heart Failure
Congestive Heart Failure
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Use of Nesiritide in the Management of Acute Diastolic Heart Failure|
- Effectiveness of nesiritide in improving symptoms, including pressure in heart and lungs, related to diastolic heart failure (condition where heart muscle is stiff and not able to relax completely, causing the pressures in heart to increase). [ Time Frame: 2 Years ]
|Study Start Date:||May 2004|
|Study Completion Date:||April 2006|
|Primary Completion Date:||April 2006 (Final data collection date for primary outcome measure)|
Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
Other Name: Natrecor
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00083772
|Study Chair:||Jean-Bernard Durand, MD||UT MD Anderson Cancer Center|